Covid antibody response to 2 or 3 doses of BioNTech-Pfizer vaccine in patients with cancer

JAMA Network

What The Study Did: This study assessed the antibody response to two or three doses of the BioNTech-Pfizer SARS-CoV-2 vaccine in 163 patients treated with anticancer agents for solid tumors.

Authors: Charlotte Fenioux, M.D., of Hôpital Henri Mondor in Créteil, France, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamaoncol.2021.7777)

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.